Post Vaccination Neutralizing Antibody Test
Bio-Plex Pro SARS-CoV-2 * Serology Assays provide COVID-19 researchers with sensitive and specific assays to monitor the immune response profile of antibodies against four viral antigens. There are three panels of isotype-specific 4 plexes that measure antibodies against the nucleocapsid, the receptor-binding domain, the receptor-binding domain, peak 1, and peak 2 of the SARS-CoV-2 viral proteins. The isotype-specific antibodies detected are IgA, IgG and IgM, which provide the spectrum of humoral response over time after administration of the COVID-19 vaccine or natural exposure to SARS-CoV-2.
Information for ordering serology tests
Bio-Plex Pro SARS-CoV-2 Neutralization Assays allow researchers to evaluate the efficacy of COVID-19 vaccines and compare the efficacy of the naturally acquired or vaccine-induced antibody response with the variants of concern that arise. These highly accurate and sensitive assays quantitatively measure neutralizing antibodies to SARS-CoV-2 against two wild-type and 11 variants of the receptor-binding domain and Peak 1 protein subunits. Antigens are coated with magnetic beads that bind to neutralizing antibodies in competition with a biotinylated ace-2 detection receptor.
SARS-CoV-2 wild-type and variant S1 and RBD antigens
In this rapidly changing landscape of SARS-CoV-2 variants, the Bio-Plex Human SARS-CoV-2 Neutralizing Antibody Custom Assay Developer Kit can be used to develop neutralization assays with any variant of interest. Comes with Bio-Plex Pro Amine Coupling Kit, Bio-Plex Pro COOH 27 Magnetic Bead Vial, and Bio-Plex Pro Serology Bead Storage Buffer.
Individual assay components are also available, offering the flexibility to test only the IgA, IgG, IgM, or neutralizing antibodies of interest. Viral protein-coated beads can be used to test multiple species-specific antibodies against SARS-CoV-2 and only need to be paired with a species-specific biotinylated detection antibody for serology assays. Bio-Plex Pro reagent kits can be used to further optimize assay setup.
Research and development of the COVID-19 vaccine and clinical trials
The immune response to vaccination is multifaceted, with elements of the innate and adaptive immune response reacting to the target immunogen. Capturing the antibody response is one aspect that can be used to determine the efficacy of a vaccine. Bio-Plex SARS-CoV-2 Serology and Neutralization Assays allow you to:
- Detects antibody response to specific viral subunits and quantitatively measures neutralizing antibodies to understand the immunogenicity profile of each protein
- Monitor dosage levels and efficacy in preclinical and clinical trials
- To determine the efficacy of the vaccine over time using seropositive results during post-marketing surveillance.